β Scribed by Vincent E. Herrin; J. Tate Thigpen
No coin nor oath required. For personal study only.
Ovarian cancer is the most common gynecologic cancer and has the highest case-fatality rate of all gynecologic malignancies: over one-half of all women diagnosed with ovarian cancer die of their disease. Chemotherapy for epithelial ovarian carcinoma has evolved rapidly during the last 15 years. Demonstrations that combination chemotherapy was superior to singleagent therapy began to improve outcome among women with this disease. By 1990, the advent of the platinum compounds had improved response rate, and the new standard of care combined platinum with alkylating agents. Recently, more significant progress has been made with utilization of the taxanes, which demonstrate not only improved response rates, but significantly prolonged survival as well. The most current clinical trials have established that taxane/platinum combination chemotherapy should be the standard of care for epithelial ovarian cancer. Recent and ongoing studies also address such issues as relative efficacy of different doses of taxanes and platinum, length of infusion for the taxanes, and interchangeability of the platinum compounds. This broad overview of the development of current standards of treatment also will address unresolved issues in this field, including intraperitoneal administration of chemotherapy and dose intensification.
π SIMILAR VOLUMES
## Abstract A chemotherapy regimen consisting of hexamethylmelamine (H) 150 mg/ m^2^ orally days 1β14, cyclophosphamide (C) 500 mg/m^2^ IV day 1 of a 28βday cycle with Adriamycin (A) 40 mg/m^2^ IV day 1 alternating with cisdiamminechloroplatinum (CβP) 50 mg/m^2^ IV day 1 every other cycle was admin
## Abstract Tumor lysis syndrome is infrequently encountered following the treatment of solid tumors. A 47βyearβold woman developed this syndrome after receiving combination chemotherapy for ovarian cancer. The levels of serum lactate dehydrogenase, uric acid, phosphate, and creatinine increased, w